Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022008 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL5363741 | 0.75 | KDM4E (0.55) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL13248484 | 0.72 | ALDH1A1 (0.51) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL13268136 | 0.72 | KDM4E (0.51) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL2269126 | 0.72 | ALDH1A1 (0.51) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL26271611 | 0.71 | KDM4E (0.41) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL17477885 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL12662934 | 0.69 | KDM4E (0.49) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL3595779 | 0.69 | KCNJ1 (0.55) | KDM4EALDH1A1L3MBTL1MEN1LMNA | |
| SCHEMBL19235503 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| US-7994187-B2 | HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-09 | — | — | US | disclosed |
| US-7994187-B2 | HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-09 | — | — | US | disclosed |
| US-7994187-B2 | HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-09 | — | — | US | disclosed |
| US-20090170855-A1 | HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170855-A1 | HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-07-02 | — | — | US | disclosed |
| EP-2004647-A1 | HIV INHIBITING 3,4-DIHYDRO-IMIDAZOÝ4,5-B¨PYRIDIN-5-ONES | Tibotec Pharmaceuticals Ltd. (IE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113290-A1 | HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170855-A1 | HIV INHIBITING 3,4-DIHYDRO-IMIDAZO[4,5-B]PYRIDIN-5-ONES | NR4A3, NR4A1, NR4A2 | KDM4E 3780/4885ALDH1A1 2020/4885L3MBTL1 804/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | KDM4E 448/4885ALDH1A1 3047/4885L3MBTL1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.